Navigation Links
TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
Date:12/2/2008

eatment periods. Adverse events were generally of mild to moderate severity and occurred in all three treatment groups and the placebo group. The frequency of adverse events was dose-ordered across the 10 mg, 15 mg and 20 mg doses, with the 20 mg group reporting the highest number of events. There were few reports of gastrointestinal complaints in any of the three dose groups.

About Xerostomia

Xerostomia, or dry mouth, is the result of decreased salivary flow and is a symptom of a number of underlying conditions. Causes of dry mouth include Sjogren's syndrome; radiation treatment to the head and neck; and HIV-related salivary gland disease. Xerostomia can also be a side effect of medications and is associated with aging.

About TorreyPines Therapeutics, Inc.

TorreyPines Therapeutics is a biopharmaceutical company committed to providing patients with better alternatives to existing therapies through the research, development and commercialization of small molecule compounds. The company's goal is to develop versatile product candidates each capable of treating a number of acute and chronic diseases and disorders such as migraine, chronic pain, muscle spasticity and rigidity, xerostomia and cognitive disorders. The company is currently developing four product candidates, two ionotropic glutamate receptor antagonists and two muscarinic receptor agonists. Further information is available at www.torreypinestherapeutics.com.

This press release contains forward-looking statements or predictions, including statements regarding the potential of NGX267 as a treatment for xerostomia, the potential of NGX267 to treat xerostomia associated with Sjogren's syndrome, radiation treatment to the head and neck, HIV-related salivary gland disease, aging, or side effects of medication, and the potential t
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Data Presented at American Headache Societys Annual Scientific Meeting Show Primary Endpoint Met as Well as Improvement on Important Secondary Endpoints in Phase IIb Acute Migraine Trial of TorreyPines Therapeutics Tezampanel
2. TorreyPines Therapeutics to Host Webinar at 11 a.m. EDT Today on the Opportunity for Treating Chronic Pain, Migraine and Muscle Spasticity Through Inhibition of Neurotransmitter Glutamate
3. TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
5. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
6. Pharmacokinetic Data Suggest NGX426, TorreyPines Therapeutics Oral Prodrug of Tezampanel, May be Effective in Treating Acute Migraine Headache
7. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
11. Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... Research and Markets  has announced the addition of ... report to their offering. Intranasal drug delivery ... of drugs for the treatment of local diseases in ... non-allergic rhinitis and sinusitis. The nose is considered to ... systematic drug delivery. Continuous technological advancement ...
(Date:8/26/2014)... , Aug. 26, 2014   Quanta Aesthetic Lasers , ... North America , expands the offerings in their robust ... which is now available for shipping to medical spas, clinics, ... . The QuantaShape is manufactured in the Chianti ... General Project .  The device was previously sold as both ...
(Date:8/26/2014)...  When it comes to diabetes supplies, innovations are often ... happens to answer a real medical need. ... market, Timesulin shows how long it,s been since your ... or double insulin doses. Very easy to use, Timesulin ... insulin pen after an injection. There is no settings ...
Breaking Medicine Technology:Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 2Global Intranasal Drug Delivery Market 2014-2018: Key Vendors are Becton, Dickinson and Company, GlaxoSmithKline, Johnson & Johnson and Novartis 3Another Italian Beauty Joins the Quanta Aesthetic Lasers Lineup 2Montméd obtains reimbursement of Timesulin, the smart insulin pen timer cap, by major insurance companies in Canada 2
... Popular antidepressants taken with tamoxifen can increase the risk ... May 30 A new study found that taking ... of breast cancer recurrence in women taking both medications. ... work effectively.(Logo: http://www.newscom.com/cgi-bin/prnh/20090530/DC24767LOGO ) ...
... Abstract # 25670ORLANDO, Fla., May 29 ... has selected new breast cancer research conducted ... in Detroit for posting on ASCO,s Web ... promising new therapeutic target for aggressive hormone ...
Cached Medicine Technology:New Research Shows Antidepressants May Thwart Breast Cancer Treatment 2New Research Shows Antidepressants May Thwart Breast Cancer Treatment 3Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy 2Scientists at The Karmanos Cancer Institute in Detroit Identify Potential New Target for Breast Cancer Therapy 3
(Date:8/27/2014)... August 27, 2014 StartX , ... and QB3 , a pioneering institute driving biotechnology ... open a life science laboratory customized for the needs ... , The 2,000 square-foot lab space, named “StartX-QB3 Labs,” ... campus and Stanford Health Care focused on developing entrepreneurs ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Humility of ... program at St. Elizabeth Boardman Health Center in Boardman ... Mall in Niles beginning Sept. 8. , SlimDown teaches ... with regard to food, physical activity and behavior. , ... St. Elizabeth Boardman Health Center and Mondays at St. ...
(Date:8/27/2014)... OR (PRWEB) August 27, 2014 A ... 24, 2014) contained a list of “Five tips for ... host of the Sharon Kleyne Hour Power of Water ... but suggests three additional tips that are seldom reported ... important. , Sharon Kleyne is Founder of ...
(Date:8/27/2014)... A new study at an Italian university finds that ... blood sodium levels, during chemotherapy are less likely to ... a comprehensive article on the new research. Click ... at Marche Polytechnic University in Ancona measured the blood ... chemotherapy at their hospital during a ten-year period. ...
(Date:8/27/2014)... NC (PRWEB) August 27, 2014 YogaVibes, ... is excited to introduce a variety of yoga classes ... Matters Yoga and Holistic Health Center. , From ... classes from senior teacher, Coral Brown, YogaVibes subscribers are ... that resonate and teachers that transform with All That ...
Breaking Medicine News(10 mins):Health News:StartX & QB3 Launch Lab for Life Science and Medical Technology Entrepreneurs 2Health News:StartX & QB3 Launch Lab for Life Science and Medical Technology Entrepreneurs 3Health News:StartX & QB3 Launch Lab for Life Science and Medical Technology Entrepreneurs 4Health News:Humility of Mary Health Partners Offers SlimDown Classes 2Health News:Water Advocate Sharon Kleyne Reports New Discoveries for Relief of Dry Dehydrated Skin 2Health News:Water Advocate Sharon Kleyne Reports New Discoveries for Relief of Dry Dehydrated Skin 3Health News:Scientists Say Blood Sodium Could Predict Mesothelioma Outcomes, According to Surviving Mesothelioma 2Health News:YogaVibes Brings All That Matters Yoga Online 2Health News:YogaVibes Brings All That Matters Yoga Online 3
... NY) Michael Brownlee, M.D., the Anita and Jack ... of Medicine of Yeshiva University, has been selected by ... prestigious David Rumbough Award for Scientific Excellence. The ... to diabetes research. Actress Dina Merrill established this ...
... University selected as winner, COLUMBUS, Ohio, May 19 ... colleges and universities across the State of Ohio, it ... organ and,tissue donors in the Ohio Donor Registry., ... Ohio, its,affiliated organ procurement organizations (OPOs) and tissue and ...
... Pharmaceuticals, Inc. (NASDAQ: NPSP) today reported the presentation of ... (DDW) Congress on GATTEX (teduglutide), a novel investigational compound ... patients with intestinal failure associated with short bowel ... evaluated two doses of GATTEX versus placebo. Results ...
... Population Health Impact,Institute (PHII), a non-profit 501(c)(3) organization, ... on June 19th entitled,"Giving Credit Where Credit is ... and Financial Outcomes Based Upon the Methods Evaluation ... the Case Management,Society of America (CMSA) Annual Conference ...
... May 19 Pennsylvania,Secretary of Health Dr. Calvin B. ... vaccination during an immunization clinic,at a shelter in Harrisburg., ... Hepatitis B and,Hepatitis A because they usually do not ... said Dr. Johnson. "While we must reach out to,vulnerable ...
... The Epilepsy,Foundation today released important information about epilepsy and ... recent news about,Senator Edward Kennedy (D-Mass)., Senator Kennedy, ... S.,Senate, reportedly experienced a seizure on Saturday. A seizure ... One in ten Americans,will have a single seizure at ...
Cached Medicine News:Health News:Dr. Michael Brownlee receives JDRF Rumbough Award for Scientific Excellence 2Health News:Do It Now College Program Registers Nearly 125,000 New Organ and Tissue Donors 2Health News:Do It Now College Program Registers Nearly 125,000 New Organ and Tissue Donors 3Health News:Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome 2Health News:Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome 3Health News:Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome 4Health News:Population Health Impact Institute to Host First Methods Evaluation Process(TM) (MEP(TM)) Workshop at Annual CMSA Conference 2Health News:PA Health Department Provides Hepatitis B Vaccinations, Discusses Risk Factors 2Health News:The Epilepsy Foundation Sheds Light on Seizures 2
The NPB-40 Handheld Pulse Oximeter is both compact and affordable. It is simple to operate, provides spot-check monitoring of SpO 2 and pulse rate, and is compact enough to fit in your pocket....
... Nellcor's most popular handheld oximeter has ... Oximetry platform and is now compatible with ... including the MAX-FAST Forehead Sensor and SoftCare ... Pulse Oximeter also incorporates Nellcor's latest advanced ...
... expanding the growing portfolio of OxiMax® ... is a compact, affordable bedside monitor. ... processing technology, it offers reliable operation ... compatible with the complete family of ...
The Model 900 is a new desk top pulse oximeter that was designed for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring. It also incorporates an LCD waveform m...
Medicine Products: